The PROTAC company Arvinas has created history by nominating two of the PROTACS to the clinic, viz. ARV-110 and ARV-471 in 2019. Recently the structures of the clinical candidates were shared. Many congratulations to the whole team on these milestones.
We at thinkMolecular got curious about the binding modes and here we show the potential modes of binding of the two clinical candidates.